Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by duskwon May 02, 2012 12:11pm
234 Views
Post# 19861800

RE: HEM for sale in 2013??

RE: HEM for sale in 2013??

As I've said a few times - the problem with HEM is their scale. As SK says, they need to keep the new products coming. R&D expenses are way too high for their revenue. However, a combined entity can leverage existing sales channels (reduce Sales & Marketting expenses), some R&D, etc. Economies of scale... 

Take another company around the same size of HEM - presumibly they are investing in R&D to create parallel product lines. Combine the two companies - no need to continue parallel developments. Net R&D expenses are signifncantly reduced. Combine sales channels - sales efficiencies are created. Larger company -> higher value purchases of raw components -> cheaper costs -> higher gross margins.

It makes so much sense... As for valuation - I would be looking for around 1.5 to 2x sales. I'd estimate around $1.50 to $2.00 as a fair offer that most shareholders would take.

 

Bullboard Posts